Loading clinical trials...
Loading clinical trials...
A 10-Month Open-Label Evaluation Of The Long-Term Safety Of Desvenlafaxine Succinate Sustained Release In Japanese Adults With Major Depressive Disorder
Conditions
Interventions
desvenlafaxine succinate sustained release tablets
Locations
17
Japan
Pfizer Investigational Site
Aichi, Japan
Pfizer Investigational Site
Chiba, Japan
Pfizer Investigational Site
Fukuoka, Japan
Pfizer Investigational Site
Fukushima, Japan
Pfizer Investigational Site
Gunma, Japan
Pfizer Investigational Site
Hiroshima, Japan
Start Date
March 1, 2009
Primary Completion Date
March 1, 2011
Completion Date
March 1, 2011
Last Updated
December 7, 2018
NCT07115329
NCT06793397
NCT07025720
NCT06780917
NCT04480918
NCT07329621
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions